|Bid||26.66 x 1000|
|Ask||26.73 x 3100|
|Day's range||26.68 - 27.10|
|52-week range||19.20 - 58.72|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||29.16|
NEW YORK, Jun 12, 2021--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021, inclusive (the "Class Period"). Investors have until June 18, 2021 to apply to the Court to be appointed as lead plaintiff
NEW YORK, Jun 11, 2021--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021, inclusive (the "Class Period") of the important June 18, 2021 lead plaintiff deadline.
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.